The study examined tirzepatide, also called Zepbound, and reported weight reductions among adolescent participants.

Health
Participants also had health conditions beyond their weight status.

The study examined tirzepatide, also called Zepbound, and reported weight reductions among adolescent participants.
Among people classified as overweight by BMI, 5.2% to 8.6% met both waist criteria for obesity-level adiposity; 1.2% to 3.1% of BMI-obese participants had no elevated waist measurements.
The exploratory analysis found ACR50 responses in 43.7% of the combination group and 15.7% of the Taltz-only group; results were not adjusted for multiple comparisons.
Gastrointestinal events led 19.3% of the lower-dose group and 20.8% of the higher-dose group to stop treatment. The drug remains investigational.